CAnceR THErapy Rating Algorithm Infrastructure
Pawel Zawadzki, Chief Executive Officer
MutationsNoMore (MNM) was born when I painfully realized that cancer treatment selection is guided by only a fraction of available genomic data, in best-case scenario.
I understood that if one can learn how to interpret all changes defining an individual tumor and translate that information into clinical data, then these Mutations are No More harmful – quite the opposite: they can be used against cancer.
This is exactly what we create at MNM – a platform which interprets all tumor mutations (100% of the genome) and directly translates it into clinics, in a form of decision-making algorithm. That requires bridging biology/medicine/genomics/machine learning/human passion – something which our interdisciplinary team is exceptional at!
1. Multi-Omics DATA INTEGRATION (genomics, transcriptomics and proteomics) in a AI-driven workflow.
2. DATA PROCESSING to produce multi-level, high-throughput and robust MultiOmics database.
3. BIOMARKER EXTRACTION FROM A COHORT OF RESPONDERS – Extraction and testing of Multi-Omics’ biomarkers associated with specific tumors and patient responses to various anti-cancer therapies.
4. BIOMARKER BUNDLING – Our platform identifies the optimal combinations of biomarker interdependencies and builds AI-powered tools to predict clinical outcomes and understand tumor physiology.
5. TESTING AND VALIDATION of the model in a clinical learning environment.
A somatic-mutational process recurrently duplicates germline susceptibility loci and tissue-specific super-enhancers in breast cancers
Genomic landscape and chronological reconstruction of driver events in multiple myeloma
HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
Autoantibodies against type I IFNs in patients with life-threatening COVID-19
Compound heterozygous GLI3 variants in siblings with thyroid hemiagenesis
The First Report of Biallelic Missense Mutations in the SFRP4 Gene Causing Pyle Disease in Two Siblings
A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection